Corvus Pharmaceuticals(CRVS) - 2024 Q1 - Earnings Call Presentation

Corvus Corporate Presentation Focus on ITK Inhibitors with Broad Opportunities in Cancer & Immune Diseases 2 Corvus ITK Inhibitor Platform Opportunity Strong IP with issued composition patents to Nov 2037; others pending 2nd and 3rd generation compounds with disease selective characteristics Experienced management with proven track record: rituximab, ibrutinib and others 3 Advancing Cancer and Immune Disease Clinical Programs | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------|------- ...